Pfizer is one of Ireland's leading employers and the largest pharmaceutical sector investor and employer. One of the first pharmaceutical companies to locate in Ireland (1969), Pfizer has a rich heritage of innovation and expansion over a forty year period. Since its acquisition of Wyeth on 15th October 2009, the business now boasts over 5,000 colleagues across 11 locations based in Cork, Dublin, Kildare, Limerick, and Sligo.*
Pfizer’s business interests in Ireland are diverse. There is a manufacturing presence in Active Pharmaceutical Ingredients, Solid Dose Pharmaceuticals, Sterile Injectibles, Nutritionals, Vaccines and Biopharmaceuticals; commercial Human Prescription, Animal Health and Consumer Health products businesses; Global Financial Services centre and a global Treasury operation.
The Irish operations manufacture some of Pfizer’s best selling and newest medicines including Lipitor (cardiovascular), Viagra (urology), Sutent (oncology), Enbrel (rheumatology) and Prevenar (vaccines). Ireland is a leading manufacturing base for Pfizer globally, exporting to global markets. Total capital investment by the company in Ireland exceeds $7billion.
* The European Commission's approval of the Pfizer acquisition of Wyeth was conditional upon Pfizer's commitment to divest several types of animal health vaccines, pharmaceuticals and medicinal feed additives in the European Economic Area or in specific Member States. Pfizer proposed to divest a number of businesses in several national markets and also offered to divest Wyeth's manufacturing facility in Sligo, Ireland. More information on the case is available at:
http://ec.europa.eu/competition/mergers/cases/index/m109.html#m_5476